DynPort Gets FDA Approval for Product to Treat Side Effects of Smallpox Vaccine

FDA has approved Vaccinia Immune Globulin Intravenous (VIGIV), the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.

VIGIV, licensed to DynPort Vaccine Company, in Frederick, Md., is made from the pooled plasma of donors who received booster immunizations with the licensed smallpox vaccine, Dryvax. This plasma contains increased levels of protective antibodies against the vaccinia virus, the live virus used in the currently available smallpox vaccine. The vaccinia virus is similar to the smallpox virus, but does not cause smallpox.

Because the smallpox vaccine is made with this live virus, even though it is a weakened virus, occasionally it can cause infections in susceptible vaccinated people or those in close contact with them. People with weakened immune systems or certain skin conditions are susceptible to vaccine complications. VIGIV helps treat these complications.